Philadelphia positive acute lymphoblastic leukaemia of childhood

British Journal of Haematology

Volumn 130, Issue 4, 2005, Pages 489-500

  Jones, Louise K ^b   Saha, Vaskar ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Childhood; Philadelphia positive acute lymphoblastic leukaemia

Indexed keywords

ALPHA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; HEAT SHOCK PROTEIN; HYDROXYUREA; IMATINIB; NILOTINIB; PREDNISOLONE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; VINCRISTINE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BIOLOGY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHILDHOOD CANCER; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DISEASE MARKER; DRUG ABSORPTION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOTRANSPLANTATION; CHILD; IMMUNOLOGY; METHODOLOGY; REMISSION; STEM CELL TRANSPLANTATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 24944533058     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05611.x     Document Type: Review

References (122)

1. Arico M. Valsecchi M.G. Camitta B. Schrappe M. Chessells J. Baruchel A. Gaynon P. Silverman L. Janka-Schaub G. Kamps W. Pui C.H. Masera G. ( 2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. New England Journal of Medicine, 342, 998 1006.
2. Arico M. Valsecchi M.G. Conter V. Rizzari C. Pession A. Messina C. Barisone E. Poggi V. De Rossi G. Locatelli F. Micalizzi M.C. Basso G. Masera G. ( 2002) Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt- Muenster protocol II. Blood, 100, 420 426.
3. Bader P. Hancock J. Kreyenberg H. Goulden N.J. Niethammer D. Oakhill A. Steward C.G. Handgretinger R. Beck J.F. Klingebiel T. ( 2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia, 16, 1668 1672.
4. Bader P. Kreyenberg H. Hoelle W. Dueckers G. Handgretinger R. Lang P. Kremens B. Dilloo D. Sykora K.W. Schrappe M. Niemeyer C. Von Stackelberg A. Gruhn B. Henze G. Greil J. Niethammer D. Dietz K. Beck J.F. Klingebiel T. ( 2004) Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy Journal of Clinical Oncology, 22, 1696 1705.
5. Bassan R. Gatta G. Tondini C. Willemze R. ( 2004) Adult acute lymphoblastic leukaemia. Critical Reviews in Oncology and Hematology, 50, 223 261.
6. Bose S. Deininger M. Gora-Tybor J. Goldman J.M. Melo J.V. ( 1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood, 92, 3362 3367.
7. von Bubnoff N. Schneller F. Peschel C. Duyster J. ( 2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet, 359, 487 491.
8. Castellanos A. Pintado B. Weruaga E. Arevalo R. Lopez A. Orfao A. Sanchez-Garcia I. ( 1997) A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product. Blood, 90, 2168 2174.
9. Cazzaniga G. Lanciotti M. Rossi V. Di Martino D. Arico M. Valsecchi M.G. Basso G. Masera G. Micalizzi C. Biondi A. ( 2002) Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response. British Journal of Haematology, 119, 445 453.
10. Champagne M.A. Capdeville R. Krailo M. Qu W. Peng B. Rosamilia M. Therrien M. Zoellner U. Blaney S.M. Bernstein M. ( 2004) Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood, 104, 2655 2660.
11. Chase A. Huntly B.J. Cross N.C. ( 2001) Cytogenetics of chronic myeloid leukaemia. Best Practice and Research Clinical Haematology, 14, 553 571.
12. Chessels J.M. Swansbury G.J. Reeves B. Bailey C.C. Richards S.M. ( 1997) Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. British Journal of Haematology, 99, 93 100.
13. Cox C.V. Evely R.S. Oakhill A. Pamphilon D.H. Goulden N.J. Blair A. ( 2004) Characterization of acute lymphoblastic leukemia progenitor cells. Blood, 104, 2919 2925.
14. Crist W. Carroll A. Shuster J. Jackson J. Head D. Borowitz M. Behm F. Link M. Steuber P. Ragab A. ( 1990) Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. Blood, 76, 489 494.
15. Dai Y. Rahmani M. Pei X.Y. Dent P. Grant S. ( 2004) Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood, 104, 509 518.
16. Daub H. Specht K. Ullrich A. ( 2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Reviews Drug Discovery, 3, 1001 1010.
17. van Delft F.W. Saha V. ( 2004) Molecular techniques to improve outcome in childhood ALL. Methods in Molecular Medicine, 91, 111 122.
18. van Delft F.W. Bellotti T. Luo Z. Jones L.K. Patel N. Yiannikouris O. Hill A.S. Hubank M. Kempski H. Fletcher D. Chaplin T. Foot N. Young B.D. Hann I.M. Gammerman A. Saha V. ( 2005) Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia. British Journal of Haematology, 130, 26 35.
19. Dombret H. Gabert J. Boiron J.M. Rigal-Huguet F. Blaise D. Thomas X. Delannoy A. Buzyn A. Bilhou-Nabera C. Cayuela J.M. Fenaux P. Bourhis J.H. Fegueux N. Charrin C. Boucheix C. Lheritier V. Esperou H. MacIntyre E. Vernant J.P. Fiere D. ( 2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood, 100, 2357 2366.
20. van Dongen J.J. Macintyre E.A. Gabert J.A. Delabesse E. Rossi V. Saglio G. Gottardi E. Rambaldi A. Dotti G. Griesinger F. Parreira A. Gameiro P. Diaz M.G. Malec M. Langerak A.W. San Miguel J.F. Biondi A. ( 1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia, 13, 1901 1928.
21. Druker B.J. Sawyers C.L. Kantarjian H. Resta D.J. Reese S.F. Ford J.M. Capdeville R. Talpaz M. ( 2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038 1042.
22. Elliott B. Jasin M. ( 2002) Double-strand breaks and translocations in cancer. Cellular and Molecular Life Sciences, 59, 373 385.
23. Enver T. Greaves M. ( 1998) Loops, lineage, and leukemia. Cell, 94, 9 12.
24. Esperou H. Boiron J.M. Cayuela J.M. Blanchet O. Kuentz M. Jouet J.P. Milpied N. Cahn J.Y. Faucher C. Bourhis J.H. Michallet M. Tanguy M.L. Vernant J.P. Gabert J. Bordigoni P. Ifrah N. Baruchel A. Dombret H. ( 2003) A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplantation, 31, 909 918.
25. Fainstein E. Marcelle C. Rosner A. Canaani E. Gale R.P. Dreazen O. Smith S.D. Croce C.M. ( 1987) A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature, 330, 386 388.
26. Fang G. Kim C.N. Perkins C.L. Ramadevi N. Winton E. Wittmann S. Bhalla K.N. ( 2000) CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood, 96, 2246 2253.
27. Fletcher J.A. Lynch E.A. Kimball V.M. Donnelly M. Tantravahi R. Sallan S.E. ( 1991) Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood, 77, 435 439.
28. Forestier E. Johansson B. Gustafsson G. Borgstrom G. Kerndrup G. Johannsson J. Heim S. ( 2000) Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group. British Journal of Haematology, 110, 147 153.
29. Gambacorti-Passerini C.B. Gunby R.H. Piazza R. Galietta A. Rostagno R. Scapozza L. ( 2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncology, 4, 75 85.
30. Garcia-Manero G. Kantarjian H.M. ( 2000) The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematology/Oncology Clinics of North America, 14, 1381 1396, x xi.
31. Gleissner B. Gokbuget N. Bartram C.R. Janssen B. Rieder H. Janssen J.W. Fonatsch C. Heyll A. Voliotis D. Beck J. Lipp T. Munzert G. Maurer J. Hoelzer D. Thiel E. ( 2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood, 99, 1536 1543.
32. Goldie J.H. Coldman A.J. ( 1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Research, 44, 3643 3653.
33. Gorre M.E. Ellwood-Yen K. Chiosis G. Rosen N. Sawyers C.L. ( 2002) BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, 100, 3041 3044.
34. Goulden N.J. Knechtli C.J. Garland R.J. Langlands K. Hancock J.P. Potter M.N. Steward C.G. Oakhill A. ( 1998) Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. British Journal of Haematology, 100, 235 244.
35. Graham S.M. Jorgensen H.G. Allan E. Pearson C. Alcorn M.J. Richmond L. Holyoake T.L. ( 2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99, 319 325.
36. Groffen J. Stephenson J.R. Heisterkamp N. de Klein A. Bartram C.R. Grosveld G. ( 1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell, 36, 93 99.
37. Gumireddy K. Baker S.J. Cosenza S.C. John P. Kang A.D. Robell K.A. Reddy M.V. Reddy E.P. ( 2005) A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proceedings of the Iona Academy of Sciences of the United States of America, 102, 1992 1997.
38. Gupta M. Kumar A. Dabadghao S. ( 2002) In vitro resistance of leukaemic blasts to prednisolone in bcr-abl positive childhood acute lymphoblastic leukaemia. Indian Journal of Medical Research, 116, 268 272.
39. Hann I. Vora A. Harrison G. Martineau M. Moorman A.V. Secker Walker L.M. Eden O. Hill F. Gibson B. Richards S. ( 2001) Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. British Journal of Haematology, 113, 103 114.
40. Heerema N.A. Harbott J. Galimberti S. Camitta B.M. Gaynon P.S. Janka-Schaub G. Kamps W. Basso G. Pui C.H. Schrappe M. Auclerc M.F. Carroll A.J. Conter V. Harrison C.J. Pullen J. Raimondi S.C. Richards S. Riehm H. Sather H.N. Shuster J.J. Silverman L.B. Valsecchi M.G. Arico M. ( 2004) Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia, 18, 693 702.
41. Heisterkamp N. Stephenson J.R. Groffen J. Hansen P.F. de Klein A. Bartram C.R. Grosveld G. ( 1983) Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature, 306, 239 242.
42. Heisterkamp N. Stam K. Groffen J. de Klein A. Grosveld G. ( 1985) Structural organization of the bcr gene and its role in the Ph' translocation. Nature, 315, 758 761.
43. Heisterkamp N. Jenster G. Kioussis D. Pattengale P.K. Groffen J. ( 1991) Human bcr-abl gene has a lethal effect on embryogenesis. Transgenic Research, 1, 45 53.
44. Hemmeryckx B. Reichert A. Watanabe M. Kaartinen V. de Jong R. Pattengale P.K. Groffen J. Heisterkamp N. ( 2002) BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl. Oncogene, 21, 3225 3231.
45. Hofmann W.K. Jones L.C. Lemp N.A. de Vos S. Gschaidmeier H. Hoelzer D. Ottmann O.G. Koeffler H.P. ( 2002) Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood, 99, 1860 1862.
46. Hofmann W.K. Komor M. Hoelzer D. Ottmann O.G. ( 2004) Mechanisms of resistance to STI571 (imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leukemia and Lymphoma, 45, 655 660.
47. Honda H. Fujii T. Takatoku M. Mano H. Witte O.N. Yazaki Y. Hirai H. ( 1995) Expression of p210bcr/abl by metallothionein promoter induced T-cell leukemia in transgenic mice. Blood, 85, 2853 2861.
48. Honda H. Oda H. Suzuki T. Takahashi T. Witte O.N. Ozawa K. Ishikawa T. Yazaki Y. Hirai H. ( 1998) Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias. Blood, 91, 2067 2075.
49. Hongo T. Okada S. Inoue N. Yamada S. Yajima S. Watanabe C. Fujii Y. Horikoshi Y. ( 2002) Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing. International Journal of Hematology, 76, 251 259.
50. Hoover R.R. Mahon F.X. Melo J.V. Daley G.Q. ( 2002) Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood, 100, 1068 1071.
51. Hotfilder M. Rottgers S. Rosemann A. Schrauder A. Schrappe M. Pieters R. Jurgens H. Harbott J. Vormoor J. ( 2005) Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells. Cancer Research, 65, 1442 1449.
52. Hu Y. Liu Y. Pelletier S. Buchdunger E. Warmuth M. Fabbro D. Hallek M. Van Etten R.A. Li S. ( 2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genetics, 36, 453 461.
53. Huettner C.S. Zhang P. Van Etten R.A. Tenen D.G. ( 2000) Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genetics, 24, 57 60.
54. Huettner C.S. Koschmieder S. Iwasaki H. Iwasaki-Arai J. Radomska H.S. Akashi K. Tenen D.G. ( 2003) Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood, 102, 3363 3370.
55. Kano Y. Akutsu M. Tsunoda S. Mano H. Sato Y. Honma Y. Furukawa Y. ( 2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 97, 1999 2007.
56. Kantarjian H.M. Talpaz M. Dhingra K. Estey E. Keating M.J. Ku S. Trujillo J. Huh Y. Stass S. Kurzrock R. ( 1991) Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood, 78, 2411 2418.
57. Kantarjian H.M. Talpaz M. O'Brien S. Giles F. Garcia-Manero G. Faderl S. Thomas D. Shan J. Rios M.B. Cortes J. ( 2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 101, 473 475.
58. Khalidi H.S. Chang K.L. Medeiros L.J. Brynes R.K. Slovak M.L. Murata-Collins J.L. Arber D.A. ( 1999) Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. American Journal of Clinical Pathology, 111, 467 476.
59. Kochling J. Konig-Merediz S.A. Stripecke R. Buchwald D. Korte A. Von Einsiedel H.G. Sack F. Henze G. Seeger K. Wittig B. Schmidt M. ( 2003) Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides. Clinical Cancer Research, 9, 3142 3149.
60. Kohlmann A. Schoch C. Schnittger S. Dugas M. Hiddemann W. Kern W. Haferlach T. ( 2004) Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia, 18, 63 71.
61. Koschmieder S. Gottgens B. Zhang P. Iwasaki-Arai J. Akashi K. Kutok J.L. Dayaram T. Geary K. Green A.R. Tenen D.G. Huettner C.S. ( 2005) Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood, 105, 324 334.
62. Kuroda J. Kimura S. Segawa H. Kobayashi Y. Yoshikawa T. Urasaki Y. Ueda T. Enjo F. Tokuda H. Ottmann O.G. Maekawa T. ( 2003) The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood, 102, 2229 2235.
63. Kurzrock R. Shtalrid M. Talpaz M. Kloetzer W.S. Gutterman J.U. ( 1987) Expression of c-abl in Philadelphia-positive acute myelogenous leukemia. Blood, 70, 1584 1588.
64. Lee S. Kim Y.-J. Min C.-K. Kim H.-J. Eom K.-S. Kim D.-W. Lee J.-W. Min W.-S. Kim C.-C. ( 2005) The impact of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, ??, 2004 2009 3785.
65. Li S. Ilaria Jr., R.L., Million R.P. Daley G.Q. Van Etten R.A. ( 1999) The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. Journal of Experimental Medicine, 189, 1399 1412.
66. Lugo T.G. Pendergast A.M. Muller A.J. Witte O.N. ( 1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 247, 1079 1082.
67. Marks D.I. Bird J.M. Cornish J.M. Goulden N.J. Jones C.G. Knechtli C.J. Pamphilon D.H. Steward C.G. Oakhill A. ( 1998) Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia. Journal of Clinical Oncology, 16, 931 936.
68. Mayerhofer M. Aichberger K.J. Florian S. Krauth M.T. Hauswirth A.W. Derdak S. Sperr W.R. Esterbauer H. Wagner O. Marosi C. Pickl W.F. Deininger M. Weisberg E. Druker B.J. Griffin J.D. Sillaber C. Valent P. ( 2005) Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. Faseb Journal, 19, 960 962, FJ Express 10.1096/fj.04-1973fje Witte O.N. ( 1989) Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Molecular and Cellular Biology, 9, 1866 1874.
69. Melo J.V. Deininger M.W. ( 2004) Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematology/Oncology Clinics of North America, 18, 545 568, vii viii.
70. Melo J.V. Gordon D.E. Cross N.C. Goldman J.M. ( 1993) The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood, 81, 158 165.
71. Melo J.V. Hochhaus A. Yan X.H. Goldman J.M. ( 1996) Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. British Journal of Haematology, 92, 684 686.
72. Mori T. Manabe A. Tsuchida M. Hanada R. Yabe H. Ohara A. Saito T. Nakazawa S. ( 2001) Allogeneic bone marrow transplantation in first remission rescues children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group (TCCSG) studies L89-12 and L92-13. Medical and Pediatric Oncology, 37, 426 431.
73. Neves H. Ramos C. da Silva M.G. Parreira A. Parreira L. ( 1999) The nuclear topography of ABL, BCR, PML, and RAR alpha genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. Blood, 93, 1197 1207.
74. Norton L. Simon R. ( 1986) The Norton-Simon hypothesis revisited. Cancer Treatment Reports, 70, 163 169.
75. Nowell P.C. Hungerford D.A. ( 1960) A minute chromosome in human granulocytic leukemia. Science, 132, 1497.
76. Ottmann O.G. Druker B.J. Sawyers C.L. Goldman J.M. Reiffers J. Silver R.T. Tura S. Fischer T. Deininger M.W. Schiffer C.A. Baccarani M. Gratwohl A. Hochhaus A. Hoelzer D. Fernandes-Reese S. Gathmann I. Capdeville R. O'Brien S.G. ( 2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 100, 1965 1971.
77. Pane F. Cimino G. Izzo B. Camera A. Vitale A. Quintarelli C. Picardi M. Specchia G. Mancini M. Cuneo A. Mecucci C. Martinelli G. Saglio G. Rotoli B. Mandelli F. Salvatore F. Foa R. ( 2005) Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia, 19, 628 635.
78. Pelz A.F. Kroning H. Franke A. Wieacker P. Stumm M. ( 2002) High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements. Annals of Hematology, 81, 147 153.
79. Perrotti D. Calabretta B. ( 2004) Translational regulation by the p210 BCR/ABL oncoprotein. Oncogene, 23, 3222 3229.
80. Petzer A.L. Gunsilius E. Hayes M. Stockhammer G. Duba H.C. Schneller F. Grunewald K. Poewe W. Gastl G. ( 2002) Low concentrations of STI571 in the cerebrospinal fluid: a case report. British Journal of Haematology, 117, 623 625.
81. Priest J.R. Robison L.L. McKenna R.W. Lindquist L.L. Warkentin P.I. LeBien T.W. Woods W.G. Kersey J.H. Coccia P.F. Nesbit Jr., M.E. ( 1980) Philadelphia chromosome positive childhood acute lymphoblastic leukemia. Blood, 56, 15 22.
82. Primo D. Tabernero M.D. Rasillo A. Sayagues J.M. Espinosa A.B. Chillon M.C. Garcia-Sanz R. Gutierrez N. Giralt M. Hagemeijer A. San Miguel J.F. Orfao A. ( 2003) Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia, 17, 1124 1129.
83. Pui C.H. Campana D. ( 2000) New definition of remission in childhood acute lymphoblastic leukemia. Leukemia, 14, 783 785.
84. Pui C.H. Crist W.M. ( 1992) Cytogenetic abnormalities in childhood acute lymphoblastic leukemia correlates with clinical features and treatment outcome. Leukemia and Lymphoma, 7, 259 274.
85. Pui C.H. Rubnitz J.E. Hancock M.L. Downing J.R. Raimondi S.C. Rivera G.K. Sandlund J.T. Ribeiro R.C. Head D.R. Relling M.V. Evans W.E. Behm F.G. ( 1998) Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 16, 3768 3773.
86. Pui C.H. Sandlund J.T. Pei D. Campana D. Rivera G.K. Ribeiro R.C. Rubnitz J.E. Razzouk B.I. Howard S.C. Hudson M.M. Cheng C. Kun L.E. Raimondi S.C. Behm F.G. Downing J.R. Relling M.V. Evans W.E. ( 2004) Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood, 104, 2690 2696.
87. Putti M.C. Rondelli R. Cocito M.G. Arico M. Sainati L. Conter V. Guglielmi C. Cantu-Rajnoldi A. Consolini R. Pession A. Zanesco L. Masera G. Biondi A. Basso G. ( 1998) Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood, 92, 795 801.
88. Ramakers-van Woerden N.L. Pieters R. Hoelzer D. Slater R.M. den Boer M.L. Loonen A.H. Harbott J. Janka-Schaub G.E. Ludwig W.D. Ossenkoppele G.J. van Wering E.R. Veerman A.J. ( 2002) In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. Medical and Pediatric Oncology, 38, 379 386.
89. van Rhee F. Hochhaus A. Lin F. Melo J.V. Goldman J.M. Cross N.C. ( 1996) p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood, 87, 5213 5217.
90. Ribeiro R.C. Abromowitch M. Raimondi S.C. Murphy S.B. Behm F. Williams D.L. ( 1987) Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood, 70, 948 953.
91. Ribeiro R.C. Broniscer A. Rivera G.K. Hancock M.L. Raimondi S.C. Sandlund J.T. Crist W. Evans W.E. Pui C.H. ( 1997) Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts. Leukemia, 11, 1493 1496.
92. Robinson H.M. Martineau M. Harris R.L. Barber K.E. Jalali G.R. Moorman A.V. Strefford J.C. Broadfield Z.J. Cheung K.L. Harrison C.J. ( 2005) Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia. Leukemia, 19, 564 571.
93. Ross M.E. Zhou X. Song G. Shurtleff S.A. Girtman K. Williams W.K. Liu H.C. Mahfouz R. Raimondi S.C. Lenny N. Patel A. Downing J.R. ( 2003) Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood, 102, 2951 2959.
94. Rowley J.D. ( 1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243, 290 293.
95. Roy A. Bradburn M. Moorman A.V. Burrett J. Love S. Kinsey S.E. Mitchell C. Vora A. Eden T. Lilleyman J.S. Hann I. Saha V. ( 2005) Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. British Journal of Haematology, 129, 35 44.
96. Saglio G. Guerrasio A. Rosso C. Zaccaria A. Tassinari A. Serra A. Rege-Cambrin G. Mazza U. Gavosto F. ( 1990) New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood, 76, 1819 1824.
97. Scherr M. Battmer K. Schultheis B. Ganser A. Eder M. ( 2005) Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Gene Therapy, 12, 12 21.
98. Schindler T. Bornmann W. Pellicena P. Miller W.T. Clarkson B. Kuriyan J. ( 2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 289, 1938 1942.
99. Schrappe M. Arico M. Harbott J. Biondi A. Zimmermann M. Conter V. Reiter A. Valsecchi M.G. Gadner H. Basso G. Bartram C.R. Lampert F. Riehm H. Masera G. ( 1998) Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood, 92, 2730 2741.
100. Secker-Walker L.M. Lawler S.D. Hardisty R.M. ( 1978) Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. British Medical Journal, 2, 1529 1530.
101. Shah N.P. Tran C. Lee F.Y. Chen P. Norris D. Sawyers C.L. ( 2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305, 399 401.
102. Shimoni A. Kroger N. Zander A.R. Rowe J.M. Hardan I. Avigdor A. Yeshurun M. Ben-Bassat I. Nagler A. ( 2003) Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia, 17, 290 297.
103. Shtivelman E. Lifshitz B. Gale R.P. Canaani E. ( 1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature, 315, 550 554.
104. Silverman L.B. Gelber R.D. Dalton V.K. Asselin B.L. Barr R.D. Clavell L.A. Hurwitz C.A. Moghrabi A. Samson Y. Schorin M.A. Arkin S. Declerck L. Cohen H.J. Sallan S.E. ( 2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood, 97, 1211 1218.
105. Takahashi N. Miura I. Saitoh K. Miura A.B. ( 1998) Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood, 92, 4758 4763.
106. Takayama N. Sato N. O'Brien S.G. Ikeda Y. Okamoto S. ( 2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. British Journal of Haematology, 119, 106 108.
107. Tanaka K. Takechi M. Hong J. Shigeta C. Oguma N. Kamada N. Takimoto Y. Kuramoto A. Dohy H. Kyo T. ( 1989) 9;22 translocation and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb survivors. Journal of Radiation Research (Tokyo), 30, 352 358.
108. Thiesing J.T. Ohno-Jones S. Kolibaba K.S. Druker B.J. ( 2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood, 96, 3195 3199.
109. Thomas D.A. Faderl S. Cortes J. O'Brien S. Giles F.J. Kornblau S.M. Garcia-Manero G. Keating M.J. Andreeff M. Jeha S. Beran M. Verstovsek S. Pierce S. Letvak L. Salvado A. Champlin R. Talpaz M. Kantarjian H. ( 2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood, 103, 4396 4407.
110. Tough I.M. Jacobs P.A. Court Brown W.M. Baikie A.G. Williamson E.R. ( 1963) Cytogenetic studies on bone-marrow in chronic myeloid leukaemia. Lancet, 1, 844 846.
111. Towatari M. Yanada M. Usui N. Takeuchi J. Sugiura I. Takeuchi M. Yagasaki F. Kawai Y. Miyawaki S. Ohtake S. Jinnai I. Matsuo K. Naoe T. Ohno R. ( 2004) Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood, 104, 3507 3512.
112. Uckun F.M. Nachman J.B. Sather H.N. Sensel M.G. Kraft P. Steinherz P.G. Lange B. Hutchinson R. Reaman G.H. Gaynon P.S. Heerema N.A. ( 1998) Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer, 83, 2030 2039.
113. Visani G. Martinelli G. Piccaluga P. Tosi P. Amabile M. Pastano R. Cavo M. Isidori A. Tura S. ( 2000) Alpha-interferon improves survival and remission duration in P-190BCR-ABL positive adult acute lymphoblastic leukemia. Leukemia, 14, 22 27.
114. Voncken J.W. Kaartinen V. Pattengale P.K. Germeraad W.T. Groffen J. Heisterkamp N. ( 1995) BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood, 86, 4603 4611.
115. Wassmann B. Scheuring U. Pfeifer H. Binckebanck A. Kabisch A. Lubbert M. Leimer L. Gschaidmeier H. Hoelzer D. Ottmann O.G. ( 2003) Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Leukemia, 17, 1919 1924.
116. Wassmann B. Pfeifer H. Scheuring U.J. Binckebanck A. Gokbuget N. Atta J. Bruck P. Rieder H. Schoch C. Leimer L. Schwerdtfeger R. Ehninger G. Lipp T. Perz J. Stelljes M. Gschaidmeier H. Hoelzer D. Ottmann O.G. ( 2004) Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with imatinib. Blood, 103, 1495 1498.
117. Wetzler M. Talpaz M. Van Etten R.A. Hirsh-Ginsberg C. Beran M. Kurzrock R. ( 1993) Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. Journal of Clinical Investigation, 92, 1925 1939.
118. Wiemels J.L. Greaves M. ( 1999) Structure and possible mechanisms of TEL-AML1 gene fusions in childhood acute lymphoblastic leukemia. Cancer Research, 59, 4075 4082.
119. Willis S. Lange T. Demehri S. Otto S. Crossman L. Niederwieser D. Stoffregen E. McWeeney S. Kovacs I. Park B. Druker B.J. Deininger M.W. ( 2005) High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood, doi: 10.1182/blook-2005-03-1036.
120. Wong S. Witte O.N. ( 2001) Modeling Philadelphia chromosome positive leukemias. Oncogene, 20, 5644 5659.
121. Wong S. Witte O.N. ( 2004) The BCR-ABL story: bench to bedside and back. Annual Review of Immunology, 22, 247 306.
122. Zeng Y. Graner M.W. Thompson S. Marron M. Katsanis E. ( 2005) Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood, 105, 2016 2022.